234 related articles for article (PubMed ID: 21371244)
1. Benign prostatic hyperplasia: racial differences in treatment patterns and prostate cancer prevalence.
Pettaway CA; Lamerato LE; Eaddy MT; Edwards JK; Hogue SL; Crane MM
BJU Int; 2011 Oct; 108(8):1302-8. PubMed ID: 21371244
[TBL] [Abstract][Full Text] [Related]
2. Clinical progression, acute urinary retention, prostate-related surgeries, and costs in patients with benign prostatic hyperplasia taking early versus delayed combination 5α-reductase inhibitor therapy and α-blocker therapy: a retrospective analysis.
Morlock R; Goodwin B; Gomez Rey G; Eaddy M
Clin Ther; 2013 May; 35(5):624-33. PubMed ID: 23583026
[TBL] [Abstract][Full Text] [Related]
3. Associations between diabetes and clinical markers of benign prostatic hyperplasia among community-dwelling Black and White men.
Sarma AV; Burke JP; Jacobson DJ; McGree ME; St Sauver J; Girman CJ; Lieber MM; Herman W; Macoska J; Montie JE; Jacobsen SJ
Diabetes Care; 2008 Mar; 31(3):476-82. PubMed ID: 18071006
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen 1.5-4.0 ng/mL: a diagnostic challenge and danger zone.
Crawford ED; Moul JW; Rove KO; Pettaway CA; Lamerato LE; Hughes A
BJU Int; 2011 Dec; 108(11):1743-9. PubMed ID: 21711431
[TBL] [Abstract][Full Text] [Related]
5. Diabetes treatment and progression of benign prostatic hyperplasia in community-dwelling black and white men.
Sarma AV; St Sauver JL; Hollingsworth JM; Jacobson DJ; McGree ME; Dunn RL; Lieber MM; Jacobsen SJ;
Urology; 2012 Jan; 79(1):102-8. PubMed ID: 22112286
[TBL] [Abstract][Full Text] [Related]
6. Potential selection bias in a community-based study of PSA levels in African-American men.
Heeringa SG; Alcser KH; Doerr K; Strawderman M; Cooney K; Medbery B; Schottenfeld D
J Clin Epidemiol; 2001 Feb; 54(2):142-8. PubMed ID: 11166529
[TBL] [Abstract][Full Text] [Related]
7. African-American men with prostate cancer have larger tumor volume than Caucasian men despite no difference in serum prostate specific antigen.
Fuletra JG; Kamenko A; Ramsey F; Eun DD; Reese AC
Can J Urol; 2018 Feb; 25(1):9193-9198. PubMed ID: 29524974
[TBL] [Abstract][Full Text] [Related]
8. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group.
Roehrborn CG; McConnell JD; Lieber M; Kaplan S; Geller J; Malek GH; Castellanos R; Coffield S; Saltzman B; Resnick M; Cook TJ; Waldstreicher J
Urology; 1999 Mar; 53(3):473-80. PubMed ID: 10096369
[TBL] [Abstract][Full Text] [Related]
9. Differences between African American and Caucasian men participating in a community-based prostate cancer screening program.
Barber KR; Shaw R; Folts M; Taylor DK; Ryan A; Hughes M; Scott V; Abbott RR
J Community Health; 1998 Dec; 23(6):441-51. PubMed ID: 9824793
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of the dual 5alpha-reductase inhibitor, dutasteride, in the treatment of benign prostatic hyperplasia in African-American men.
Roehrborn CG; Ray P
Prostate Cancer Prostatic Dis; 2006; 9(4):432-8. PubMed ID: 16983393
[TBL] [Abstract][Full Text] [Related]
11. Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride.
Kuiper JG; Bezemer ID; Driessen MT; Vasylyev A; Roehrborn CG; Penning-van Beest FJ; Herings RM
BMC Urol; 2016 Aug; 16(1):53. PubMed ID: 27580700
[TBL] [Abstract][Full Text] [Related]
12. [The changes of prostate specific antigen (PSA) after treatment with alpha 1-adrenergic receptor antagonists in men with 4.0-9.9 ng/ml PSA level--a study for comparison of benign prostatic hyperplasia/lower urinary tract symptom (BPH/LUTS) and prostate cancer].
Hanai T; Matsumoto S; Shouji S; Usui Y; Tang XY; Kato Y; Iguchi M; Uemura H; Terachi T
Hinyokika Kiyo; 2009 Apr; 55(4):187-91. PubMed ID: 19462822
[TBL] [Abstract][Full Text] [Related]
13. Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.
Logan YT; Belgeri MT
Am J Geriatr Pharmacother; 2005 Jun; 3(2):103-14. PubMed ID: 16129387
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer in African-American men: outcome following radiation therapy with or without adjuvant androgen ablation.
Zagars GK; Pollack A; Pettaway CA
Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):517-23. PubMed ID: 9806509
[TBL] [Abstract][Full Text] [Related]
16. Cathepsin B expression is similar in African-American and Caucasian prostate cancer patients.
Sinha AA; Morgan JL; Buus RJ; Ewing SL; Fernandes ET; Le C; Wilson MJ
Anticancer Res; 2007; 27(5A):3135-41. PubMed ID: 17970054
[TBL] [Abstract][Full Text] [Related]
17. Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry.
Sartor O; Armstrong AJ; Ahaghotu C; McLeod DG; Cooperberg MR; Penson DF; Kantoff PW; Vogelzang NJ; Hussain A; Pieczonka CM; Shore ND; Quinn DI; Small EJ; Heath EI; Tutrone RF; Schellhammer PF; Harmon M; Chang NN; Sheikh NA; Brown B; Freedland SJ; Higano CS
Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):517-526. PubMed ID: 32111923
[TBL] [Abstract][Full Text] [Related]
18. Significance of histological prostatitis in patients with urinary retention and underlying benign prostatic hyperplasia or adenocarcinoma of the prostate.
van Vuuren SP; Heyns CF; Zarrabi AD
BJU Int; 2012 Apr; 109(8):1194-7. PubMed ID: 21851551
[TBL] [Abstract][Full Text] [Related]
19. Racial and Ethnic Disparities in Prostate Cancer Outcomes in the Veterans Affairs Health Care System.
Yamoah K; Lee KM; Awasthi S; Alba PR; Perez C; Anglin-Foote TR; Robison B; Gao A; DuVall SL; Katsoulakis E; Wong YN; Markt SC; Rose BS; Burri R; Wang C; Aboiralor O; Fink AK; Nickols NG; Lynch JA; Garraway IP
JAMA Netw Open; 2022 Jan; 5(1):e2144027. PubMed ID: 35040965
[TBL] [Abstract][Full Text] [Related]
20. Race and socioeconomic status are independently associated with benign prostatic hyperplasia.
Fowke JH; Murff HJ; Signorello LB; Lund L; Blot WJ
J Urol; 2008 Nov; 180(5):2091-6; discussion 2096. PubMed ID: 18804231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
